Lilly moves next-gen obesity drug forward after standout mid-stage data

Eli Lilly (NYSE: LLY) is preparing to start Phase III trials of its experimental obesity therapy eloralintide by year-end, following Phase II results that showed weight reductions of up to 20% over 48 weeks. The once-weekly injection was well-tolerated, strengthening confidence in Lilly’s expanding obesity portfolio.

Eloralintide works through amylin receptors in the brain, a different mechanism from incretin-based drugs such as Lilly’s Zepbound (tirzepatide) and Novo Nordisk’s (NOV: N) Wegovy (semaglutide).

Lilly says the drug’s selectivity could make it an alternative or complementary option to GLP-1 therapies, widening its reach in weight management. Kenneth Custer, head of cardiometabolic health at Lilly, said “molecule specificity” will be key to shaping the next wave of obesity treatments.